Literature DB >> 26760827

Immune activation in the central nervous system throughout the course of HIV infection.

Serena S Spudich1.   

Abstract

PURPOSE OF REVIEW: Robust and dynamic innate and adaptive responses characterize the acute central nervous system (CNS) response to HIV and other viral infections. In a state of chronic infection or viral latency, persistent immune activation associates with abnormality in the CNS. Understanding this process is critical, as immune-mediated abnormality in nonrenewable CNS cells may result in long-term neurologic sequelae for HIV-infected individuals. RECENT
FINDINGS: In humans, immune activation is reduced by suppressive combination antiretroviral therapy, but persists at abnormally elevated levels on treatment. CNS immune activation is initiated in acute infection and progressively increases until combination antiretroviral therapy is started. Newly identified characteristics of the CNS immune surveillance network include features of homeostasis and function of brain microglial cells, lymphatic drainage from CNS to cervical lymph nodes, and cells in cerebrospinal fluid associated with neurocognitive impairment.
SUMMARY: More research is required to determine whether early intervention to reduce infection limits the immunopathology established by sustained immune responses that ultimately fail to resolve infection, and to unravel mechanisms of persistent immune activation during treated HIV so that strategies can be developed to therapeutically protect the brain.

Entities:  

Mesh:

Year:  2016        PMID: 26760827      PMCID: PMC4773903          DOI: 10.1097/COH.0000000000000243

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  63 in total

1.  Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment initiated during primary HIV-1 infection.

Authors:  R H Enting; J M Prins; S Jurriaans; K Brinkman; P Portegies; J M Lange
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

2.  Central nervous system viral invasion and inflammation during acute HIV infection.

Authors:  Victor Valcour; Thep Chalermchai; Napapon Sailasuta; Mary Marovich; Sukalaya Lerdlum; Duanghathai Suttichom; Nijasri C Suwanwela; Linda Jagodzinski; Nelson Michael; Serena Spudich; Frits van Griensven; Mark de Souza; Jerome Kim; Jintanat Ananworanich
Journal:  J Infect Dis       Date:  2012-05-02       Impact factor: 5.226

3.  Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.

Authors:  Aylin Yilmaz; Chris Verhofstede; Antonio D'Avolio; Victoria Watson; Lars Hagberg; Dietmar Fuchs; Bo Svennerholm; Magnus Gisslén
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12-15       Impact factor: 3.731

4.  Subcortical brain atrophy persists even in HAART-regulated HIV disease.

Authors:  James T Becker; Joanne Sanders; Sarah K Madsen; Ann Ragin; Lawrence Kingsley; Victoria Maruca; Bruce Cohen; Karl Goodkin; Eileen Martin; Eric N Miller; Ned Sacktor; Jeffery R Alger; Peter B Barker; Priyanka Saharan; Owen T Carmichael; Paul M Thompson
Journal:  Brain Imaging Behav       Date:  2011-06       Impact factor: 3.978

5.  Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy.

Authors:  Arvid Edén; Richard W Price; Serena Spudich; Dietmar Fuchs; Lars Hagberg; Magnus Gisslén
Journal:  J Infect Dis       Date:  2007-12-15       Impact factor: 5.226

6.  Rapid inflammasome activation in microglia contributes to brain disease in HIV/AIDS.

Authors:  John G Walsh; Stacey N Reinke; Manmeet K Mamik; Brienne A McKenzie; Ferdinand Maingat; William G Branton; David I Broadhurst; Christopher Power
Journal:  Retrovirology       Date:  2014-05-13       Impact factor: 4.602

7.  Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.

Authors:  Ana Canestri; François-Xavier Lescure; Stephane Jaureguiberry; Antoine Moulignier; Corinne Amiel; Anne Geneviève Marcelin; Gilles Peytavin; Roland Tubiana; Gilles Pialoux; Christine Katlama
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

8.  Minocycline inhibition of monocyte activation correlates with neuronal protection in SIV neuroAIDS.

Authors:  Jennifer H Campbell; Tricia H Burdo; Patrick Autissier; Jeffrey P Bombardier; Susan V Westmoreland; Caroline Soulas; R Gilberto González; Eva-Maria Ratai; Kenneth C Williams
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

9.  Therapeutic antiviral T cells noncytopathically clear persistently infected microglia after conversion into antigen-presenting cells.

Authors:  Jasmin Herz; Kory R Johnson; Dorian B McGavern
Journal:  J Exp Med       Date:  2015-06-29       Impact factor: 14.307

10.  Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid.

Authors:  Oliver M Grauer; Doris Reichelt; Ute Grüneberg; Hubertus Lohmann; Tilman Schneider-Hohendorf; Andreas Schulte-Mecklenbeck; Catharina C Gross; Sven G Meuth; Heinz Wiendl; Ingo W Husstedt
Journal:  Ann Clin Transl Neurol       Date:  2015-08-18       Impact factor: 4.511

View more
  34 in total

1.  The role of catecholamines in HIV neuropathogenesis.

Authors:  R Nolan; P J Gaskill
Journal:  Brain Res       Date:  2018-04-27       Impact factor: 3.252

Review 2.  Treating HIV Infection in the Central Nervous System.

Authors:  A Calcagno; G Di Perri; S Bonora
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

Review 3.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

4.  Global HIV neurology: a comprehensive review.

Authors:  Kiran T Thakur; Alexandra Boubour; Deanna Saylor; Mitashee Das; David R Bearden; Gretchen L Birbeck
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

5.  Impact of Perinatally Acquired HIV Disease Upon Longitudinal Changes in Memory and Executive Functioning.

Authors:  Kathleen M Malee; Miriam C Chernoff; Patricia A Sirois; Paige L Williams; Patricia A Garvie; Betsy L Kammerer; Lynnette L Harris; Molly L Nozyce; Cenk Yildirim; Sharon L Nichols
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-01       Impact factor: 3.731

Review 6.  HIV-associated neurocognitive disorder.

Authors:  David B Clifford
Journal:  Curr Opin Infect Dis       Date:  2017-02       Impact factor: 4.915

7.  Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART).

Authors:  E Merlini; F Iannuzzi; A Calcagno; F Bai; M Trunfio; A d'Arminio Monforte; S Bonora; Giulia Marchetti
Journal:  J Neurovirol       Date:  2018-07-09       Impact factor: 2.643

Review 8.  Opioid and chemokine regulation of cortical synaptodendritic damage in HIV-associated neurocognitive disorders.

Authors:  Bradley Nash; Lindsay Festa; Chihyang Lin; Olimpia Meucci
Journal:  Brain Res       Date:  2019-08-26       Impact factor: 3.252

9.  Remitted depression and cognition in HIV: The role of cortisol and inflammation.

Authors:  Leah H Rubin; Scott A Langenecker; K Luan Phan; Sheila M Keating; Gretchen N Neigh; Kathleen M Weber; Pauline M Maki
Journal:  Psychoneuroendocrinology       Date:  2020-02-07       Impact factor: 4.905

10.  Immune activation and HIV: an enduring relationship.

Authors:  Irini Sereti; Marcus Altfeld
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.